These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 421172)

  • 21. Active experimental inhibition of cancer by corynebacterium parvum.
    Wrba H; Dutter A
    Osterr Z Onkol; 1977 Oct; 4(2-3):60-1. PubMed ID: 579449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of killed Corynebacterium parvum suspensions in a murine mammary adenocarcinoma CaD2) system.
    Purnell DM; Otterstrom JR; Bartlett GL; Kreider JW
    J Natl Cancer Inst; 1976 Jun; 56(6):1171-5. PubMed ID: 994219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the removal of the primary tumor and immunotherapy with Corynebacterium parvum on metastatic tumor proliferation.
    Hashimoto O; Miwa H; Orita K
    Acta Med Okayama; 1983 Aug; 37(4):335-40. PubMed ID: 6624533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of prolonged Corynebacterium parvum and cyclophosphamide administration on spontaneously occurring metastases.
    Wolmark N; Fisher B
    Surg Forum; 1975; 26():136-8. PubMed ID: 1216089
    [No Abstract]   [Full Text] [Related]  

  • 25. Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Dec; 38(12):4522-6. PubMed ID: 719637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antitumoral activity of various doses of corynebacterium parvum as a function of the age of mice].
    Stiffel C; Chalvet H; Mazurek C
    Ann Inst Pasteur Immunol (1985); 1985; 136D(1):19-27. PubMed ID: 3840664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum.
    Likhite VV; Halpern BN
    Cancer Res; 1974 Feb; 34(2):341-4. PubMed ID: 4810906
    [No Abstract]   [Full Text] [Related]  

  • 28. Correlation of antitumor chemoimmunotherapy with bone marrow macrophage precursor cell stimulation and macrophage cytotoxicity.
    Fisher B; Wolmark N
    Cancer Res; 1976 Jul; 36(7 PT 1):2241-7. PubMed ID: 1277129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation therapy and Corynebacterium parvum in the treatment of murine tumors.
    Suit HD; Sedlacek RS; Silobrcic V; Linggood RM
    Cancer; 1976 Jun; 37(6):2573-9. PubMed ID: 949676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of the expression of adoptive tumor rejection immunity by recipient cyclophosphamide-sensitive cells.
    Boyer CM; Kreider JW; Bartlett GL
    Cancer Res; 1982 Jun; 42(6):2211-5. PubMed ID: 7042079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bladder tumor model response to immunotherapy.
    deKernion JB; Ramming KP; Fraser K
    Natl Cancer Inst Monogr; 1978 Dec; (49):333. PubMed ID: 748789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of radiation responses of murine tumors by misonidazole (Ro 07-0582), host immune capability, and Corynebacterium parvum.
    Stone HB; Milas L
    J Natl Cancer Inst; 1978 Apr; 60(4):887-93. PubMed ID: 633396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rejection of tumors and metastases in Fischer 344 rats following intratumor administration of killed Corynebacterium parvum.
    Likhite VV
    Int J Cancer; 1974 Nov; 14(5):684-90. PubMed ID: 4459281
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of intracerebrally injected Corynebacterium parvum on the development and growth of metastatic brain tumor in mice.
    Kennedy JD; Sutton RC; Conley FK
    Neurosurgery; 1989 Nov; 25(5):709-14. PubMed ID: 2586725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of tumor metastasis after surgical removal of primary tumor by using in vitro activated macrophages.
    Okuno K; Hashimoto T; Qian JH; Tsuchida T; Fujiwara H; Hamaoka T
    Jpn J Clin Oncol; 1985 Mar; 15(1):87-94. PubMed ID: 3981817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effects of surgical intervention and removal of the primary tumor, and the effectiveness of Corynebacterium parvum on metastatic tumor proliferation].
    Hashimoto O
    Nihon Geka Gakkai Zasshi; 1983 Jul; 84(7):577-90. PubMed ID: 6676630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoimmunotherapy of murine mammary adenocarcinomas.
    Ames IH
    Anticancer Res; 2004; 24(4):2249-56. PubMed ID: 15330169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proceedings: Treatment of a metastasizing murine tumour with Corynebacterium parvum.
    Sadler TE; Castro JE
    Br J Cancer; 1975 Feb; 31(2):264. PubMed ID: 1164486
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.